JP7025356B2 - インターロイキン‐４受容体への結合のための抗体 - Google Patents

インターロイキン‐４受容体への結合のための抗体 Download PDF

Info

Publication number
JP7025356B2
JP7025356B2 JP2018564202A JP2018564202A JP7025356B2 JP 7025356 B2 JP7025356 B2 JP 7025356B2 JP 2018564202 A JP2018564202 A JP 2018564202A JP 2018564202 A JP2018564202 A JP 2018564202A JP 7025356 B2 JP7025356 B2 JP 7025356B2
Authority
JP
Japan
Prior art keywords
seq
antibody
chain variable
variable region
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520816A (ja
Inventor
チェン，ウェイ
パン，ウビン
ヤン，シン
チェン，ヤン
チャン，リミン
ジアン，ジエ
Original Assignee
スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド filed Critical スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド
Publication of JP2019520816A publication Critical patent/JP2019520816A/ja
Priority to JP2022019435A priority Critical patent/JP2022065063A/ja
Application granted granted Critical
Publication of JP7025356B2 publication Critical patent/JP7025356B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
JP2018564202A 2016-06-08 2017-06-08 インターロイキン‐４受容体への結合のための抗体 Active JP7025356B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022019435A JP2022065063A (ja) 2016-06-08 2022-02-10 インターロイキン‐４受容体への結合のための抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610399254.4A CN107474134B (zh) 2016-06-08 2016-06-08 用于结合白细胞介素4受体的抗体
CN201610399254.4 2016-06-08
PCT/CN2017/087592 WO2017211319A1 (zh) 2016-06-08 2017-06-08 用于结合白细胞介素4受体的抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022019435A Division JP2022065063A (ja) 2016-06-08 2022-02-10 インターロイキン‐４受容体への結合のための抗体

Publications (2)

Publication Number Publication Date
JP2019520816A JP2019520816A (ja) 2019-07-25
JP7025356B2 true JP7025356B2 (ja) 2022-03-03

Family

ID=60577597

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018564202A Active JP7025356B2 (ja) 2016-06-08 2017-06-08 インターロイキン‐４受容体への結合のための抗体
JP2022019435A Pending JP2022065063A (ja) 2016-06-08 2022-02-10 インターロイキン‐４受容体への結合のための抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022019435A Pending JP2022065063A (ja) 2016-06-08 2022-02-10 インターロイキン‐４受容体への結合のための抗体

Country Status (18)

Country Link
US (4) US20190177408A1 (enExample)
EP (2) EP3470430B1 (enExample)
JP (2) JP7025356B2 (enExample)
KR (2) KR102502988B1 (enExample)
CN (2) CN107474134B (enExample)
AU (2) AU2017276473B2 (enExample)
BR (1) BR112018074325A2 (enExample)
CA (1) CA3026568A1 (enExample)
ES (1) ES3007134T3 (enExample)
IL (1) IL263268B2 (enExample)
MX (1) MX2018014941A (enExample)
MY (1) MY189035A (enExample)
PH (1) PH12018502544B1 (enExample)
SA (1) SA518400605B1 (enExample)
SG (1) SG11201810855VA (enExample)
UA (1) UA124835C2 (enExample)
WO (1) WO2017211319A1 (enExample)
ZA (1) ZA201808209B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
CN110872349A (zh) * 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN111494626B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
CN111592597B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
AU2021244266A1 (en) 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
CN114957472B (zh) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
US20230374144A1 (en) * 2020-09-10 2023-11-23 Staidson (Beijing) Biopharmaceutical Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof
AU2021357078A1 (en) 2020-10-05 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
MX2024001189A (es) 2021-07-26 2024-02-27 Sanofi Biotechnology Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
AU2022333073A1 (en) 2021-08-23 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20240099290A (ko) 2021-10-20 2024-06-28 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법
WO2023130010A1 (en) 2021-12-30 2023-07-06 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
KR20240167717A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 항체 생산을 위한 세포 배양 방법
WO2023215267A1 (en) 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Anti-interleukin-4 receptor (il-4r) antibody formulations
US20240199688A1 (en) 2022-05-02 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
TW202421660A (zh) 2022-07-08 2024-06-01 美商再生元醫藥公司 藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法
EP4580659A1 (en) 2022-08-29 2025-07-09 Sanofi Biotechnology Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
WO2024097714A1 (en) 2022-11-01 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
IL320670A (en) 2022-11-23 2025-07-01 Regeneron Pharma Methods for enhancing bone growth by administering an IL-4R antagonist
TW202502819A (zh) 2023-03-22 2025-01-16 法商賽諾菲生物技術公司 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
KR20250164835A (ko) 2023-03-27 2025-11-25 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여하여 호산구성 위장염을 치료하는 방법
WO2025096932A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
JP2007534305A (ja) 2003-11-07 2007-11-29 アムジェン インコーポレイテッド サル免疫グロブリン配列
JP2007534306A (ja) 2003-11-07 2007-11-29 イミュネックス・コーポレーション インターロイキン−４受容体を結合する抗体
JP2014501512A (ja) 2010-11-23 2014-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体に対するヒト抗体
JP2015505303A (ja) 2011-12-13 2015-02-19 ピエリス アーゲー Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (zh) * 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110008326A1 (en) * 2008-04-02 2011-01-13 Oliver Hill Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
RU2620071C2 (ru) * 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
ES2981062T3 (es) 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
AU2015209124A1 (en) 2014-01-27 2016-08-18 Medimmune, Llc Dipeptidyl peptidase-4 (DPP4/CD26) as a peripheral biomarker of IL-13 activation in asthmatic lung
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
CN108339118A (zh) 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
US12216129B2 (en) 2018-11-09 2025-02-04 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human IL-4 receptor alpha
EP3935085A1 (en) 2019-03-06 2022-01-12 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
CN111686247B (zh) 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
JP2007534305A (ja) 2003-11-07 2007-11-29 アムジェン インコーポレイテッド サル免疫グロブリン配列
JP2007534306A (ja) 2003-11-07 2007-11-29 イミュネックス・コーポレーション インターロイキン−４受容体を結合する抗体
JP2014501512A (ja) 2010-11-23 2014-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体に対するヒト抗体
JP2015505303A (ja) 2011-12-13 2015-02-19 ピエリス アーゲー Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Light chain variable region of IL-4 receptor antibody, T57P substitution，DATABASE Geneseq [Online], accession no. AEA08961，2005年07月28日

Also Published As

Publication number Publication date
BR112018074325A2 (pt) 2019-10-01
CA3026568A1 (en) 2017-12-14
EP3470430A1 (en) 2019-04-17
ES3007134T3 (en) 2025-03-19
SG11201810855VA (en) 2019-01-30
NZ749151A (en) 2025-05-30
KR102417217B1 (ko) 2022-07-05
UA124835C2 (uk) 2021-12-01
KR20220093409A (ko) 2022-07-05
US20200255514A1 (en) 2020-08-13
PH12018502544A1 (en) 2019-10-07
CN113372446A (zh) 2021-09-10
RU2019100002A (ru) 2020-07-14
AU2017276473B2 (en) 2024-06-20
US20240190954A1 (en) 2024-06-13
CN107474134A (zh) 2017-12-15
EP4420671A3 (en) 2024-11-20
KR20190015757A (ko) 2019-02-14
JP2019520816A (ja) 2019-07-25
AU2024205464A1 (en) 2024-08-22
CN107474134B (zh) 2021-07-27
US11866491B2 (en) 2024-01-09
MY189035A (en) 2022-01-20
US10774141B2 (en) 2020-09-15
JP2022065063A (ja) 2022-04-26
US20210079088A1 (en) 2021-03-18
EP4420671A2 (en) 2024-08-28
ZA201808209B (en) 2019-09-25
RU2019100002A3 (enExample) 2020-10-07
PH12018502544B1 (en) 2023-08-18
WO2017211319A1 (zh) 2017-12-14
MX2018014941A (es) 2019-03-07
AU2017276473A1 (en) 2019-01-03
EP3470430B1 (en) 2024-08-28
EP3470430A4 (en) 2020-06-03
IL263268B2 (en) 2023-10-01
KR102502988B1 (ko) 2023-02-23
IL263268B1 (en) 2023-06-01
SA518400605B1 (ar) 2022-10-30
IL263268A (en) 2018-12-31
US20190177408A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
JP7025356B2 (ja) インターロイキン‐４受容体への結合のための抗体
CN111393526B (zh) 抗gdf15中和性单克隆抗体及其应用
WO2017215524A1 (zh) 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
KR101681331B1 (ko) 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
CN107596365A (zh) 关节炎治疗
Ratsimandresy et al. Anti-cytokine therapeutics: history and update
WO2016031250A1 (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
TW201919698A (zh) 異位性皮炎之治療
WO2014139425A1 (zh) 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
RU2774446C2 (ru) Антитело для специфического связывания с рецептором интерлейкина 4
HK40115869A (en) Antibody for binding to interleukin 4 receptor
HK1250166B (zh) 用於结合白细胞介素4受体的抗体
JP2023547176A (ja) アトピー性皮膚炎又は関連症状を治療及び／又は防止するためのｉｌ－１８アンタゴニストの使用
HK1250166A1 (zh) 用於结合白细胞介素4受体的抗体
WO2025221933A1 (en) Antibodies and polypeptides comprising variant fc regions
WO2024130541A1 (zh) 一种靶向IL-1α的抗体或其抗原结合片段及其应用
CN120659807A (zh) 一种靶向tslp的单克隆抗体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220210

R150 Certificate of patent or registration of utility model

Ref document number: 7025356

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350